南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停

MSC外泌体miR-21a-5p通过靶向PFKM抑制糖酵解减轻肾纤维化

Bone marrow mesenchymal stem cell-derived exosomal miR-21a-5p alleviates renal fibrosis by attenuating glycolysis by targeting PFKM

Xu Shihao, Cheuk Yin Celeste, Jia Yichen, Chen Tian, Chen Juntao, Luo Yongsheng, Cao Yirui, Guo Jingjing, Dong Lijun, Zhang Yi, Shi Yi, Rong Ruiming

Journal:Cell Death & Disease

IF:9.69

DOI:10.1038/s41419-022-05305-7

PMID:36253358

Published:2022-10-17

research field:免疫学呼吸生物学血液学疫苗研究生物技术病毒学

Abstract

Renal fibrosis is a common pathological feature and outcome of almost all chronic kidney diseases, and it is characterized by metabolic reprogramming toward aerobic glycolysis. Mesenchymal stem cell-derived exosomes (MSC-Exos) have been proposed as a promising therapeutic approach for renal fibrosis. In this study, we investigated the effect of MSC-Exos on glycolysis and the underlying mechanisms. We demonstrated that MSC-Exos significantly ameliorated unilateral ureter obstruction (UUO)-induced renal fibrosis by inhibiting glycolysis in tubular epithelial cells (TECs). miRNA sequencing showed that miR-21a-5p was highly enriched in MSC-Exos. Mechanistically, miR-21a-5p repressed the expression of phosphofructokinase muscle isoform (PFKM), a rate-limiting enzyme of glycolysis, thereby attenuating glycolysis in TECs. Additionally, knockdown of miR-21a-5p abolished the renoprotective effect of MSC-Exos. These findings revealed a novel role for MSC-Exos in the suppression of glycolysis, providing a new insight into the treatment of renal fibrosis.

本文使用的Yeasen产品

购物车
客服
转染试用